These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 14507605)

  • 1. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.
    Cole SR; Hernán MA; Robins JM; Anastos K; Chmiel J; Detels R; Ervin C; Feldman J; Greenblatt R; Kingsley L; Lai S; Young M; Cohen M; Muñoz A
    Am J Epidemiol; 2003 Oct; 158(7):687-94. PubMed ID: 14507605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count.
    Cole SR; Hernán MA; Margolick JB; Cohen MH; Robins JM
    Am J Epidemiol; 2005 Sep; 162(5):471-8. PubMed ID: 16076835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death.
    Cole SR; Jacobson LP; Tien PC; Kingsley L; Chmiel JS; Anastos K
    Am J Epidemiol; 2010 Jan; 171(1):113-22. PubMed ID: 19934191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Marginal structural models application to estimate the effects of antiretroviral therapy in 5 cohorts of HIV seroconverters].
    Pérez-Hoyos S; Ferreros I; Hernán MA;
    Gac Sanit; 2007; 21(1):76-83. PubMed ID: 17306191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death.
    Cole SR; Hudgens MG; Tien PC; Anastos K; Kingsley L; Chmiel JS; Jacobson LP
    Am J Epidemiol; 2012 Mar; 175(5):381-90. PubMed ID: 22302074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model.
    Cole SR; Hernán MA; Anastos K; Jamieson BD; Robins JM
    Am J Epidemiol; 2007 Jul; 166(2):219-27. PubMed ID: 17478436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death.
    Westreich D; Cole SR; Young JG; Palella F; Tien PC; Kingsley L; Gange SJ; Hernán MA
    Stat Med; 2012 Aug; 31(18):2000-9. PubMed ID: 22495733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
    Porter K; Babiker A; Bhaskaran K; Darbyshire J; Pezzotti P; Porter K; Walker AS;
    Lancet; 2003 Oct; 362(9392):1267-74. PubMed ID: 14575971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time scale and adjusted survival curves for marginal structural cox models.
    Westreich D; Cole SR; Tien PC; Chmiel JS; Kingsley L; Funk MJ; Anastos K; Jacobson LP
    Am J Epidemiol; 2010 Mar; 171(6):691-700. PubMed ID: 20139124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus.
    López-Gatell H; Cole SR; Hessol NA; French AL; Greenblatt RM; Landesman S; Preston-Martin S; Anastos K
    Am J Epidemiol; 2007 May; 165(10):1134-42. PubMed ID: 17339383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
    Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.
    Wada N; Jacobson LP; Cohen M; French A; Phair J; Muñoz A
    Am J Epidemiol; 2013 Jan; 177(2):116-25. PubMed ID: 23287403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural accelerated failure time models for survival analysis in studies with time-varying treatments.
    Hernán MA; Cole SR; Margolick J; Cohen M; Robins JM
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):477-91. PubMed ID: 15660442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study.
    Junghans C; Low N; Chan P; Witschi A; Vernazza P; Egger M
    AIDS; 1999 Dec; 13(18):2547-54. PubMed ID: 10630524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.